Interaksi Fosamprenavir dan Nirmatrelvir dan ritonavir

Fosamprenavir dan Nirmatrelvir dan ritonavir: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.

Mayor

Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.

Apa kata label FDA

Dari label Fosamprenavir (Fosamprenavir Calcium) · berlaku sejak 2026-06-30

Mayor

The list of contraindicated drugs applies to the use of fosamprenavir calcium with or without ritonavir, unless otherwise indicated.

Kontraindikasimenyebut Nirmatrelvir dan ritonavirLihat label di DailyMed
Mayor

If fosamprenavir calcium is coadministered with ritonavir, reference should be made to the full prescribing information for ritonavir for additional contraindications.

Kontraindikasimenyebut Nirmatrelvir dan ritonavirLihat label di DailyMed
Mayor

Fosamprenavir calcium is contraindicated when coadministered with the following drugs: Alpha 1-adrenoreceptor antagonist: Alfuzosin Antiarrhythmics: Flecainide (with ritonavir ), propafenone (with ritonavir ) Antimycobacterial: Rifampin Antipsychotic: Lurasidone (with ritonavir ), pimozide Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine…

Kontraindikasimenyebut Nirmatrelvir dan ritonavirLihat label di DailyMed
Mayor

Review ritonavir contraindications when used in combination.

Kontraindikasimenyebut Nirmatrelvir dan ritonavirLihat label di DailyMed
Mayor

…clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications. clinically significant adverse reactions from greater exposures of fosamprenavir calcium/ritonavir. loss of therapeutic effect of fosamprenavir calcium/ritonavir and possible development of resistance.

Peringatan dan perhatianmenyebut Nirmatrelvir dan ritonavirLihat label di DailyMed

Dari label Nirmatrelvir dan ritonavir (Paxlovid) · berlaku sejak 2026-02-19

Moderat

• HIV-1 Drug Resistance: PAXLOVID use may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Risk of HIV-1 Resistance Development Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection [see Contraindications (4) and Drug Interactions (7) ] .

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Monitor for increased PAXLOVID or protease inhibitor adverse events .

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Anti-HIV protease inhibitors atazanavir, darunavir, tipranavir ↑ protease inhibitor For further information, refer to the respective protease inhibitors' prescribing information.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Anti-HIV efavirenz, maraviroc, nevirapine, zidovudine, bictegravir/ emtricitabine/ tenofovir ↑ efavirenz ↑ maraviroc ↑ nevirapine ↓ zidovudine ↑ bictegravir ↔ emtricitabine ↑ tenofovir For further information, refer to the respective anti-HIV drugs prescribing information.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.